Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?

Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope

(2015) Luke N. Robinson et al.   CELL

Immunogenicity and Efficacy of Flagellin-Envelope Fusion Dengue Vaccines in Mice and Monkeys

(2015) Ge Liu et al.   Clinical and Vaccine Immunology

Expression and characterization of an M cell-specific ligand-fused dengue virus tetravalent epitope using Saccharomyces cerevisiae

(2015) Ngoc-Luong Nguyen et al.   JOURNAL OF BIOSCIENCE AND BIOENGINEERING

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

(2015) Sri Rezeki Hadinegoro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

(2015) Luis Villar et al.   NEW ENGLAND JOURNAL OF MEDICINE

The dengue vaccine pipeline: Implications for the future of dengue control

(2015) Lauren M. Schwartz et al.   VACCINE

Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice

(2015) Roland Zuest et al.   VACCINE

Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models

(2015) William W Tang et al.   Current Opinion in Virology

Households as Foci for Dengue Transmission in Highly Urban Vietnam

(2015) Katherine L. Anders et al.   PLoS Neglected Tropical Diseases

The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2

(2014) Lázaro Gil et al.   IMMUNOLOGY AND CELL BIOLOGY

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

(2014) Maria Rosario Capeding et al.   LANCET

A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

(2014) Wanwisa Dejnirattisai et al.   NATURE IMMUNOLOGY

Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine

(2014) Hui Zhao et al.   PLoS One

Global spread of dengue virus types: mapping the 70 year history

(2014) Jane P. Messina et al.   TRENDS IN MICROBIOLOGY

Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity

(2014) Chen-Yi Chiang et al.   VACCINE

Capsid protein: Evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys

(2014) Lázaro Gil et al.   VIROLOGY

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico

(2014) Gustavo H Dayan et al.   Human Vaccines & Immunotherapeutics

Dengue Virus Neutralizing Antibody Levels Associated with Protection from Infection in Thai Cluster Studies

(2014) Darunee Buddhari et al.   PLoS Neglected Tropical Diseases

First Experimental In Vivo Model of Enhanced Dengue Disease Severity through Maternally Acquired Heterotypic Dengue Antibodies

(2014) Jowin Kai Wei Ng et al.   PLoS Pathogens

Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera

(2014) Ruklanthi de Alwis et al.   PLoS Pathogens

Mouse Models to Study Dengue Virus Immunology and Pathogenesis

(2014) Raphaël M. Zellweger et al.   Frontiers in Immunology

A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates

(2013) Hsin-Wei Chen et al.   ARCHIVES OF VIROLOGY

Dengue vaccines: recent developments, ongoing challenges and current candidates

(2013) Monica A McArthur et al.   Expert Review of Vaccines

A Shorter Time Interval Between First and Second Dengue Infections Is Associated With Protection From Clinical Illness in a School-based Cohort in Thailand

(2013) Kathryn B. Anderson et al.   JOURNAL OF INFECTIOUS DISEASES

Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity

(2013) N. G. Reich et al.   Journal of the Royal Society Interface

A Mouse Monoclonal Antibody against Dengue Virus Type 1 Mochizuki Strain Targeting Envelope Protein Domain II and Displaying Strongly Neutralizing but Not Enhancing Activity

(2013) Atsushi Yamanaka et al.   JOURNAL OF VIROLOGY

An Alphavirus Vector-Based Tetravalent Dengue Vaccine Induces a Rapid and Protective Immune Response in Macaques That Differs Qualitatively from Immunity Induced by Live Virus Infection

(2013) L. J. White et al.   JOURNAL OF VIROLOGY

C5a receptor-targeting ligand-mediated delivery of dengue virus antigen to M cells evokes antigen-specific systemic and mucosal immune responses in oral immunization

(2013) Sae-Hae Kim et al.   MICROBES AND INFECTION

Induction of robust immunity by the emulsification of recombinant lipidated dengue-1 envelope protein domain III

(2013) Chen-Yi Chiang et al.   MICROBES AND INFECTION

The global distribution and burden of dengue

(2013) Samir Bhatt et al.   NATURE

Key roles of adjuvants in modern vaccines

(2013) Steven G Reed et al.   NATURE MEDICINE

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

(2013) D. Weiskopf et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice

(2013) Nancy Coconi-Linares et al.   VACCINE

Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore

(2013) Anke Harenberg et al.   Human Vaccines & Immunotherapeutics

DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice

(2013) Jazmín García-Machorro et al.   Human Vaccines & Immunotherapeutics

Lipidated Dengue-2 Envelope Protein Domain III Independently Stimulates Long-Lasting Neutralizing Antibodies and Reduces the Risk of Antibody-Dependent Enhancement

(2013) Chen-Yi Chiang et al.   PLoS Neglected Tropical Diseases

Symptomatic Versus Inapparent Outcome in Repeat Dengue Virus Infections Is Influenced by the Time Interval between Infections and Study Year

(2013) Magelda Montoya et al.   PLoS Neglected Tropical Diseases

A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults

(2012) Stephen J. Thomas et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice

(2012) L. Gil et al.   JOURNAL OF GENERAL VIROLOGY

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

(2012) Arunee Sabchareon et al.   LANCET

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

(2012) R. de Alwis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Structural Basis for Serotype-Specific Neutralization of Dengue Virus by a Human Antibody

(2012) E. P. Teoh et al.   Science Translational Medicine

Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo

(2012) Katherine L. Williams et al.   VIROLOGY

Dengue-1 Envelope Protein Domain III along with PELC and CpG Oligodeoxynucleotides Synergistically Enhances Immune Responses

(2012) Chen-Yi Chiang et al.   PLoS Neglected Tropical Diseases

Clinical and Virological Study of Dengue Cases and the Members of Their Households: The Multinational DENFRAME Project

(2012) Philippe Dussart et al.   PLoS Neglected Tropical Diseases

Interference and Facilitation Between Dengue Serotypes in a Tetravalent Live Dengue Virus Vaccine Candidate

(2011) K. B. Anderson et al.   JOURNAL OF INFECTIOUS DISEASES

A Novel Single-Dose Dengue Subunit Vaccine Induces Memory Immune Responses

(2011) Chen-Yi Chiang et al.   PLoS One

The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice

(2011) Lidice Bernardo et al.   VACCINE

Next generation dengue vaccines: A review of candidates in preclinical development

(2011) Julia Schmitz et al.   VACCINE

Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults

(2011) Christine B. Turley et al.   VACCINE

Determinants of Inapparent and Symptomatic Dengue Infection in a Prospective Study of Primary School Children in Kamphaeng Phet, Thailand

(2011) Timothy P. Endy et al.   PLoS Neglected Tropical Diseases

Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus

(2010) Laura Lazo et al.   ARCHIVES OF VIROLOGY

The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity

(2010) Martina Beltramello et al.   Cell Host & Microbe

Domain III of the envelope protein as a dengue vaccine target

(2010) Maria G Guzman et al.   Expert Review of Vaccines

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

(2010) Wellington Sun et al.   Human vaccines & immunotherapeutics

Flagellin as an Adjuvant: Cellular Mechanisms and Potential

(2010) S. B. Mizel et al.   JOURNAL OF IMMUNOLOGY

CD4+ T Cells Are Not Required for the Induction of Dengue Virus-Specific CD8+ T Cell or Antibody Responses but Contribute to Protection after Vaccination

(2010) L. E. Yauch et al.   JOURNAL OF IMMUNOLOGY

Genotype-Specific Neutralization and Protection by Antibodies against Dengue Virus Type 3

(2010) James D. Brien et al.   JOURNAL OF VIROLOGY

Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes

(2010) Scott B Halstead et al.   LANCET INFECTIOUS DISEASES

Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans

(2010) W. Dejnirattisai et al.   SCIENCE

Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys

(2010) David E. Clements et al.   VACCINE

The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1

(2010) Bimmi Shrestha et al.   PLoS Pathogens

Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification

(2010) Scott J. Balsitis et al.   PLoS Pathogens

Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice

(2009) L. Gil et al.   INTERNATIONAL IMMUNOLOGY

A Protective Role for Dengue Virus-Specific CD8+ T Cells

(2009) L. E. Yauch et al.   JOURNAL OF IMMUNOLOGY

Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens

(2009) Wayne D. Crill et al.   PLoS One

A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice

(2009) Iris Valdés et al.   VIROLOGY

Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody

(2009) W.M.P.B. Wahala et al.   VIROLOGY

A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model

(2009) Daniel H. Libraty et al.   PLOS MEDICINE

Structural proteomics of dengue virus

(2008) Rushika Perera et al.   CURRENT OPINION IN MICROBIOLOGY

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

(2008) Bruno Guy et al.   VACCINE